Increased activation of mTORC1 is observed in numerous human cancers due to gain-of-function mutations in oncogenes (PI3K, AKT or Ras) and/or loss-of-function mutations in tumor suppressors (PTEN, LKB1, or TSC1/2), upstream regulators of mTORC1 [3]. Here, STK11 is linked to cancer.